Beijing Deli Furui Pharmaceutical Technology Co. Ltd.

Main purpose: To use docetaxel injection concentrate (self-emulsifying type) (specification: 1mL: 20mg) developed and produced by Beijing Deli Yingjie Pharmaceutical Technology Co., Ltd. as the test preparation, and docetaxel injection (specification: 0.5mL: 20mg, Taxotere®) produced by Sanofi-Aventis Deutschland GmbH as the reference preparation, and conduct an in vivo pharmacokinetic comparison study in accordance with the relevant provisions of the bioequivalence test to investigate the pharmacokinetic behavior of docetaxel in patients diagnosed with malignant tumors and ready to receive docetaxel chemotherapy, and evaluate the bioequivalence of the two preparations. Secondary purpose: To study the safety of the test preparation docetaxel injection concentrate (self-emulsifying type) and the reference preparation docetaxel injection (trade name: Taxotere®) in patients diagnosed with malignant tumors and ready to receive docetaxel chemotherapy

Main purpose: This study used a randomized open, four-sequence, four-period, fasting and postprandial dosing design to compare the differences in exposure of 2 tablets of celecoxib tablets (I) (60 mg/tablet) developed by Beijing Delishena Pharmaceutical Technology Co., Ltd. and produced by Anhui Sihuan Kebao Pharmaceutical Co., Ltd. and 1 tablet of celecoxib capsules (200 mg/capsule, Celebrex®) produced by Pfizer Pharmaceuticals LLC in healthy subjects under fasting and postprandial conditions. The food effects of celecoxib tablets (I) and celecoxib capsules under fasting/postprandial conditions were evaluated respectively. Secondary purpose: To observe the safety of single oral administration of test drugs and control drugs in healthy volunteers.

Main purpose The docetaxel injection (trade name: Taxotere®) (specification: 0.5mL: 20mg) produced by Sanofi-Aventis Deutschland GmbH was used as the reference preparation. According to the relevant provisions of the bioequivalence test, the docetaxel injection concentrate (self-emulsifying type) (specification: 1mL: 20mg) developed by Beijing Deli Yingjie Pharmaceutical Technology Co., Ltd. was used as the test preparation for in vivo pharmacokinetic comparison study to investigate the pharmacokinetic behavior of docetaxel in patients with advanced breast cancer or non-small cell lung cancer and evaluate the bioequivalence of the two preparations. Secondary purpose To study the safety of the test preparation docetaxel injection concentrate (self-emulsifying type) and the reference preparation docetaxel injection (trade name: Taxotere®) in patients with advanced breast cancer or non-small cell lung cancer.